China SXT Pharmaceuticals, Inc. balance sheet SXTC

Annual Quarterly

As of Mar 31, 2026, China SXT Pharmaceuticals, Inc. had total assets of $34.8 million and total liabilities of $5.0 million. Total assets were up 60.4% from a year earlier. Stockholders' equity was $29.7 million. It held $28.2 million in cash and investments against $1.1 million of total debt, net cash of $27.1 million. The current ratio, current assets divided by current liabilities, was 7.93.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Mar 31, 2026
FY 2025
Mar 31, 2025
FY 2024
Mar 31, 2024
FY 2023
Mar 31, 2023
FY 2022
Mar 31, 2022
FY 2021
Mar 31, 2021
FY 2020
Mar 31, 2020
FY 2019
Mar 31, 2019
Assets
Cash
28
+55.7%
18
+49.9%
12
—
—
13
+83.3%
7
-21.6%
9
Cash and investments
28
+55.7%
18
+49.9%
12
—
—
13
+83.3%
7
-21.6%
9
Receivables
1
-28.4%
1
-1.0%
1
-2.2%
1
-59.7%
3
-26.0%
5
+18.0%
4
-8.6%
4
Inventory
1
-6.2%
1
+4.2%
1
+49.6%
1
-47.8%
1
+18.4%
1
-3.7%
1
-11.4%
1
Total current assets
35
+62.0%
21
+49.6%
14
-27.1%
20
-13.1%
22
-3.4%
23
+18.3%
20
+26.0%
16
Property and equipment, net
0
-34.4%
0
-45.7%
0
-65.8%
1
-21.6%
1
-14.3%
1
-9.0%
2
+35.9%
1
Total assets
35
+60.4%
22
-6.3%
23
-21.7%
30
-11.9%
34
-2.9%
35
+59.2%
22
+24.2%
17
Liabilities and equity
Accounts payable
0
-57.0%
1
-9.5%
1
-7.1%
1
-7.0%
1
+1.8%
1
-25.0%
2
+15.2%
2
Total current liabilities
4
-27.7%
6
-32.5%
9
-38.6%
14
-15.3%
17
-7.8%
19
+51.5%
12
+94.0%
6
Total liabilities
5
-18.9%
6
-32.3%
9
-38.1%
15
-13.2%
17
-7.9%
19
+51.1%
12
+93.3%
6
Stockholders' equity
30
+92.4%
15
+10.8%
14
-5.2%
15
-8.7%
16
+0.8%
16
+69.8%
9
-15.4%
11
Debt
Debt due within a year
0
-74.9%
1
+40.3%
1
+474.6%
0
+890.7%
0
-69.3%
0
-46.0%
0
+92.8%
0
Long-term debt
1
+569.4%
0
-17.8%
0
-0.6%
0
—
—
—
—
Lease liabilities
0
-31.3%
0
-25.1%
0
-22.9%
0
—
—
—
—
Total debt
1
-33.5%
2
+23.9%
1
+127.0%
1
+3286.2%
0
-69.3%
0
-46.0%
0
+92.8%
0
Net cash
27
+64.8%
16
+53.2%
11
—
—
13
+84.8%
7
-22.1%
9
Ratios
Current ratio
7.93x
3.54x
1.60x
1.35x
1.31x
1.25x
1.60x
2.47x
Debt to equity
0.04x
0.11x
0.10x
0.04x
0.00x
0.00x
0.01x
0.00x
Return on equity
-20.89%
-21.40%
-22.24%
-40.40%
-35.67%
-17.22%
-109.43%
13.86%
Return on assets
-17.85%
-15.25%
-13.40%
-20.08%
-17.10%
-7.95%
-47.40%
8.81%
Book value per share
—
168.27
1.01
32.12
7.92
20.56
1.08
0.49
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SXTC (Nasdaq)
Fiscal year ends
March 31
Incorporated in
Virgin Islands, British
Headquarters
Taizhou
SEC filer status
Non-accelerated filer
SEC CIK
1723980

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.